Eric Miller, MD

Clinical fellow in Hematology and Medical Oncology at @TischCancer and @IcahnMountSinai | Alumni of @BIDMC_IM and @uazmedphx

[Eric Miller, MD @ericjmiller7]

@TumorBoardTues @MattGalsky @tompowles1 @PGrivasMDPhD @DanielPetrylak @koshkin85 @DrRosenbergMSK @DrScottTagawa @drmnstein @MichvdHeijden @shilpaonc @y_loriot @sonpavde @OncoBellmunt @AndreaNecchi @kalasri3 @zklaassen_md @drenriquegrande @CAP_MDNY #PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 https://t.co/Iqyop5qD0D
➡️Your patient with HER2+ mUC (IHC 3+) progresses on adjuvant gem/cis and 1L nivolumab
➡️He achieves partial response to disitamab vedotin before discontinuing for neuropathy
🧐Which would you select next

[Eric Miller, MD @ericjmiller7]

@TumorBoardTues @MattGalsky @tompowles1 @PGrivasMDPhD @DanielPetrylak @koshkin85 @DrRosenbergMSK @DrScottTagawa @drmnstein @MichvdHeijden @shilpaonc @y_loriot @sonpavde @OncoBellmunt @AndreaNecchi @kalasri3 @zklaassen_md @drenriquegrande @CAP_MDNY #PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 https://t.co/P1v8C95eRJ
👉🏽ALL CME🔗 https://t.co/Iqyop5qD0D
🤔Which of the following ADCs target📷HER2📷❓